Further Research With Tab-Cel in EBV+ Post-Transplant Lymphoproliferative Disease
AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed further research with tab-cel, including study 205.
Stem Cell Therapy Device Restores Insulin Production in T1 Diabetes: James Shapiro, MD
The Director of the Islet Transplant Program at the University of Alberta discussed the implantable VC-02 device's success in type 1 diabetes.
Improving Cancer Survival With Immunotherapy: Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed the growing presence of CAR T-cell therapies in lung cancer and melanoma.
Using Cell Therapy to Reduce Immunosuppression in Living Kidney Transplant Participants
Scott Requadt, chief executive officer, Talaris Therapeutics, discussed the long-term follow-up and FREEDOM-1 trials of FCR-001.
Gene Therapy for GM1 Gangliosidosis: Latest Updates
Ralph Laufer, PhD, chief scientific officer, Lysogene, discussed gene therapy programs in GM1 gangliosidosis and Fragile X syndrome.
Trials Examining Cilta-Cel in Relapsed/Refractory Multiple Myeloma: Mansi R. Shah, MD
The hematologist/oncologist from Rutgers Cancer Institute of New Jersey discussed ongoing research examining the CAR T-cell therapy ciltacabtagene autoleucel.
Unmet Needs with Cellular Therapy in Metastatic Epithelial Cancer: Christian S. Hinrichs, MD
The chief of Cancer Immunotherapy at Rutgers Cancer Institute of New Jersey discussed unmet needs with cellular therapies in metastatic epithelial cancer.
The Need for Academic and Community Collaboration With CAR T-Cell Therapy: Bijal Shah, MD; Michael Wang, MD
The hematologists from Moffitt Cancer Center and MD Anderson Cancer Center discussed the need for collaboration between academic and community practices for patients who receive CAR T-cell therapy.
Strategies to Reverse Multiple Sclerosis Neurodegeneration: Robert Zivadinov, MD, PhD
The director of the Buffalo Neuroimaging Analysis Center and professor of Universtiy of Buffalo discussed avenues of research into reversing neurodegeneration in MS.
Utility of CART22-65s and huCART19 in R/R ALL: Noelle V. Frey, MD, MSCE
The associate professor from Perelman School of Medicine, University of Pennsylvania, discussed co-administered CART22-65s and huCART19 in relapsed/refractory acute lymphoblastic leukemia.
Addressing Unmet Needs in Hemophilia: Guy Young, MD
The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed the ATLAS-INH study of fitusiran.
Long Term Follow-Up of Axi-Cel in R/R Non-Hodgkin Lymphoma : Sattva S. Neelapu, MD
The professor from The University of Texas MD Anderson Cancer Center discussed long-term follow-up analysis of the phase 2 ZUMA-5 trial.
Assessing Axi-Cel in R/R LBC Lymphoma in ZUMA-7: Frederick Locke, MD
The vice chair, Blood and Marrow Transplant and Cellular Immunotherapy Program, and co-leader, Immuno-Oncology, Moffitt Cancer Center, discussed the results of the phase 3 ZUMA-7 trial.
Safety Advantages of Tab-Cel Over Other T-Cell Therapies in EBV+ PTLD
AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed safety findings from the phase 3 ALLELE study.
Challenges in Managing High-Risk Mantle Cell Lymphoma: Bijal Shah, MD; Michael Wang, MD
The hematologist from Moffitt Cancer Center and MD Anderson Cancer Center discussed CAR T-cell therapy and other treatment options for MCL.
Initial Results of CT-0508 in HER2+ Solid Tumors: Kim A. Reiss Binder, MD
The oncologist from Abramson Cancer Center, Penn Medicine discussed the initial results of the phase 1 trial of CT-0508 in HER2-overexpressing solid tumors.
Using HLA LOH as a Biomarker in Targeting Cancers: Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed the role of HLA loss in common cancers and its use as a biomarker.
Managing CAR T-Associated Neurotoxicity and CRS: Bijal Shah, MD, MS; Michael Wang, MD
The hematologists from Moffitt Cancer Center and MD Anderson discussed managing CAR T-cell therapy-associated toxicities.
CAR T-Cell Therapy Associated Toxicities: Bijal Shah, MD, MS; Michael Wang, MD
The hematologists from Moffitt Cancer Center and The University of Texas MD Anderson Cancer Center discussed CAR T-associated toxicities.
Reprogramming the Immune System for Kidney Transplant and Scleroderma
Scott Requadt, chief executive officer, Talaris Therapeutics, discussed the company’s goal to reprogram the immune system.
Gene Therapy for Sanfilippo Syndrome: Latest Updates
Ralph Laufer, PhD, chief scientific officer, Lysogene, discussed LYS-SAF302, its mechanism of action, trial data, and further research.
Importance of Screening and Early Treatment in Genetic Disorders: Paul Wuh-Liang Hwu, MD, PhD
The professor from National Taiwan University Hospital discussed gene therapy studies in AADC deficiency, Parkinson disease, SMA, and Pompe disease.
Identifying Future Patients for Tmod Cell Therapy in BASECAMP-1: Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed the BASECAMP study and how it will inform future studies assessing Tmod technology.
Mesenchymal Stem Cells and Other Upcoming Treatments for Progressive MS: Jeffrey Cohen, MD
The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed upcoming new therapies for relapsing MS.
Raising Awareness of CAR T Therapy for Mantle Cell Lymphoma: Luhua Wang, MD
The professor from The University of Texas MD Anderson Cancer Center discussed growing awareness of CAR T-cell therapy among community oncologists and patients with mantle cell lymphoma.
Advantages of T-Cell Immunotherapy Over CAR T-Cells
AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed the advantages of tab-cel over other T-cell therapies.
Advantages of Concurrently Investigating Gene Therapies in Dogs and Humans
Dan Oliver, cofounder and chief executive officer, Rejuvenate Bio, discussed the advantages of developing gene therapies for both dogs and humans.
CAR T and Other Emerging Therapies in R/R Multiple Myeloma: Kenneth H. Shain, MD, PhD
The hematologist/oncologist at Moffitt Cancer Center discussed emerging therapies for patients with relapsed/refractory multiple myeloma.
Utility of CAR T-Cell Therapy in Relapsed Multiple Myeloma: Thomas G. Martin, MD
The co-leader of Cancer Immunology & Immunotherapy Program, UCSF Helen Diller Family Comprehensive Cancer Center discussed he utility of CAR T-cell therapy in late relapsed multiple myeloma.
Developing Gene Therapies for Indications With Unmet Needs
The chief executive and scientific officers of Lysogene discussed Lysogene’s patient-focused therapy development.
